|
|
Volumn 75 Suppl 1, Issue , 2007, Pages 69-78
|
|
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
a
a
NONE
(Germany)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE;
OMEPRAZOLE;
PANTOPRAZOLE;
ADULT;
AGED;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG ADMINISTRATION;
FEMALE;
FOLLOW UP;
GASTROESOPHAGEAL REFLUX;
HOSPITALIZATION;
HUMAN;
MALE;
MIDDLE AGED;
MULTICENTER STUDY;
PROBABILITY;
QUESTIONNAIRE;
RANDOMIZED CONTROLLED TRIAL;
RECURRENT DISEASE;
REFERENCE VALUE;
SENSITIVITY AND SPECIFICITY;
STANDARD;
TREATMENT OUTCOME;
2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES;
ADULT;
AGED;
CROSS-OVER STUDIES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
FOLLOW-UP STUDIES;
GASTROESOPHAGEAL REFLUX;
HUMANS;
MALE;
MIDDLE AGED;
OMEPRAZOLE;
PROBABILITY;
QUESTIONNAIRES;
RECURRENCE;
REFERENCE VALUES;
SENSITIVITY AND SPECIFICITY;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
|
EID: 34347379359
PISSN: None
EISSN: 14219867
Source Type: Journal
DOI: 10.1159/000101085 Document Type: Article |
|
Times cited : (16)
|
|
References (0)
|
